Averitas Pharma aims to submit a supplemental new drug application (sNDA) in 2026. QUTENZA (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with ...

- The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...

“You should also have an ophthalmologist to refer to when you have a patient with thyroid eye disease that needs urgent ...

Chemotherapy for three months demonstrates lower side effects, suggesting its use as standard care compared with six months.

Report on how AI is redefining market landscape - The global gastroparesis drugs market  size is estimated to grow by USD 1.42 billion from 2024-2028, according to Technavio. The market is estimated ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

However, as for traditional chemotherapy, ADCs can also induce treatment resistance and side effects such as neuropathy.

Diabetes is a lifelong condition that causes your blood sugar levels to become too high - and some of the warning signs can appear in the feet. Here are the symptoms to look out for ...

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments. One of these, lecanemab ...

July 17, 2024 — A medication used to treat diabetic neuropathy may make chemotherapy treatments more effective for patients with lung cancer, according to new ... New Study Finds 40-Percent of ...

Patients with Huntington’s disease have a genetic mutation that triggers proteins to misfold and clump together in the brain.

Brad Axis Brain and Back Institute +1 (817) 502-7411 ... Visit us on social media: Facebook X LinkedIn YouTube ...